Drug intelligence / Profile preview

VI-0609

Development stage: Phase 2
Lead developer: VIVUS LLC
Modality: Small Molecules
Administration: Intravenous

Overview

VI-0609 is an innovative ethanol-free formulation of carmustine for injection developed by VIVUS. This formulation is expected to decrease infusion-related side effects. It is being developed for use in bone marrow transplant preparation and for treating lymphomas, specifically Hodgkin's lymphoma and Non-Hodgkin lymphoma.

Targets

DNA

Beyond the preview

Go deeper on VI-0609.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VI-0609.

Explore the full profile